MaxCyte (NASDAQ:MXCT) Stock Rating Lowered by Wall Street Zen

MaxCyte (NASDAQ:MXCT) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of MaxCyte in a research note on Monday, December 29th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $7.00.

MaxCyte Stock Down 6.7%

Shares of NASDAQ MXCT opened at $0.78 on Friday. The business’s 50 day moving average price is $1.05 and its two-hundred day moving average price is $1.38. The company has a market cap of $83.20 million, a PE ratio of -1.77 and a beta of 1.22. MaxCyte has a twelve month low of $0.64 and a twelve month high of $3.58.

Institutional Investors Weigh In On MaxCyte

A number of institutional investors have recently made changes to their positions in MXCT. Prudential Financial Inc. acquired a new position in shares of MaxCyte in the second quarter valued at approximately $26,000. State of Wyoming acquired a new stake in MaxCyte during the 2nd quarter worth approximately $38,000. Dynamic Technology Lab Private Ltd bought a new stake in MaxCyte in the 2nd quarter valued at $40,000. Kwmg LLC boosted its stake in MaxCyte by 75.8% in the 3rd quarter. Kwmg LLC now owns 25,833 shares of the company’s stock valued at $41,000 after purchasing an additional 11,135 shares during the period. Finally, BNP Paribas Financial Markets grew its holdings in MaxCyte by 266.6% in the 2nd quarter. BNP Paribas Financial Markets now owns 26,008 shares of the company’s stock valued at $57,000 after buying an additional 18,913 shares in the last quarter. Institutional investors own 68.81% of the company’s stock.

MaxCyte Company Profile

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.